AP&T: Anti-TNF therapy can reduce clinical symptoms and outcomes after COVID-19 in patients with autoimmune disease

Most people infected with the new coronavirus ( COVID-19 ) are either asymptomatic or present with mild symptoms, including fever, cough, myalgia, fatigue, loss of smell, and more
.

However, a significant proportion of those infected have the potential to develop severe disease requiring hospitalization or admission to intensive care units for treatment

Most people infected with the new coronavirus ( COVID-19 ) are either asymptomatic or present with mild symptoms, including fever, cough, myalgia, fatigue, loss of smell, and more

 

The researchers conducted a systematic search of the literature in the PubMed and SCOPUS databases using specific keywords
.

All reports of COVID-19 outcomes in patients receiving anti-TNF therapy through September 2021 were included in this meta-analysis

 

In total, 84 studies were included in systematic reviews and 35 studies were included in meta-analyses
.

Findings found that patients receiving anti-TNF therapy were less likely to be hospitalized in COVID-19 cases compared with non-anti-TNF therapy (eight studies, 2555 patients, OR = 0.

^{2 2 2}

Figure: Meta-analysis shows that anti-TNF therapy reduces the incidence of severe COVID-19

 

This study confirms that TNF-α inhibitors are associated with lower hospitalization rates and severe COVID-19 than any other treatment for the underlying inflammatory disease
.

This study confirms that TNF-α inhibitors are associated with lower hospitalization rates and severe COVID-19 than any other treatment for the underlying inflammatory disease
.

Original source:

Georgios Kokkotis.

Systematic review with meta-analysis: COVID-19 outcomes in patients receiving anti-TNF treatments.
Leave a comment here